Cyclacel Pharmaceuticals (CYCC) Stock Price, News & Analysis

Company Overview

Cyclacel Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of novel cancer therapies that target key mechanisms of cell division. Founded in 1996, the company has built a pipeline of experimental small-molecule inhibitors designed to disrupt the activity of cyclin-dependent kinases (CDKs) and other cell cycle regulators. These targeted agents are intended to selectively halt the proliferation of tumor cells while minimizing effects on healthy tissue.

The company’s most advanced programs include fadraciclib (formerly CYC065), an oral CDK2/9 inhibitor in Phase 1/2 studies for advanced solid tumors and hematologic malignancies, and CYC140, a novel allosteric inhibitor of aurora kinases under early clinical evaluation. Cyclacel’s research and development efforts leverage in-house discovery platforms as well as strategic collaborations with academic institutions and contract research organizations. This collaborative model supports rapid translation of laboratory findings into clinical candidates.

Cyclacel is headquartered in Berkeley Heights, New Jersey, with additional research operations in Dundee, Scotland, reflecting its UK-US footprint. Over the years, the company has advanced multiple compounds into human trials, demonstrating its ability to move promising molecules through preclinical stages. Under its experienced management team, Cyclacel continues to explore combination regimens and biomarker-driven approaches to enhance the therapeutic potential of its pipeline agents for patients with hard-to-treat cancers.

Key Stats

• Today's Range: N/A
• 50-Day Range: $6.36 to $9.81
• 52-Week Range: N/A
• Volume: 220,161 shs
• Average Volume: 82,670 shs
• Market Capitalization: $14.43 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Hold

Cyclacel Pharmaceuticals Stock Analysis - MarketRank™

Cyclacel Pharmaceuticals scored higher than 3% of companies evaluated by MarketBeat, and ranked 949th out of 952 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Cyclacel Pharmaceuticals.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Cyclacel Pharmaceuticals is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Cyclacel Pharmaceuticals is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

9.35% of the float of Cyclacel Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Cyclacel Pharmaceuticals has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Cyclacel Pharmaceuticals has recently increased by 49.77%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Cyclacel Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Cyclacel Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

9.35% of the float of Cyclacel Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Cyclacel Pharmaceuticals has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Cyclacel Pharmaceuticals has recently increased by 49.77%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

Search Interest

Only 1 people have searched for CYCC on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Cyclacel Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $83,430.00 in company stock.

Percentage Held by Insiders

51.20% of the stock of Cyclacel Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 23.58% of the stock of Cyclacel Pharmaceuticals is held by institutions.

CYCC Stock Analysis - Frequently Asked Questions

How were Cyclacel Pharmaceuticals' earnings last quarter?

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) announced its quarterly earnings data on Wednesday, August, 13th. The biotechnology company reported ($0.98) earnings per share for the quarter, beating the consensus estimate of ($72.00) by $71.02.

When did Cyclacel Pharmaceuticals' stock split?

Shares of Cyclacel Pharmaceuticals reverse split before market open on Monday, July 7th 2025.The 1-15 reverse split was announced on Wednesday, July 2nd 2025. The number of shares owned by shareholders was adjusted after the market closes on Thursday, July 3rd 2025. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

How do I buy shares of Cyclacel Pharmaceuticals?

Shares of CYCC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Cyclacel Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Cyclacel Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), GE Aerospace (GE), Broadcom (AVGO), Advanced Micro Devices (AMD), CymaBay Therapeutics (CBAY) and Arista Networks (ANET).

Company Calendar

• Last Earnings: 8/13/2025
• Today: 10/11/2025
• Next Earnings (Estimated): 11/10/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CYCC
• CIK: 1130166
• Web: www.cyclacel.com
• Phone: (908) 517-7330
• Fax: 866-271-3466
• Employees: 14
• Year Founded: 1992

Profitability

• EPS (Trailing Twelve Months): ($839.58)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$11.21 million
• Net Margins: N/A
• Pretax Margin: -54,220.00%
• Return on Equity: -723.64%
• Return on Assets: -145.51%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.77
• Quick Ratio: 5.77

Sales & Book Value

• Annual Sales: $40 thousand
• Price / Sales: 360.64
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($58.87) per share
• Price / Book: -0.11

Miscellaneous

• Outstanding Shares: 2,240,000
• Free Float: 1,093,000
• Market Cap: $14.43 million
• Optionable: Optionable
• Beta: 0.15